Enterprise Value

974.7M

Cash

371M

Avg Qtr Burn

N/A

Short % of Float

18.11%

Insider Ownership

19.39%

Institutional Own.

90.63%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

sNDA

Submission

WAKIX® (pitolisant) Details
EDS in Idiopathic Hypersomnia

Phase 3

Update

WAKIX® (pitolisant) Details
Genetic disorder, Rare genetic disease, Prader-Willi syndrome, Excessive daytime sleepiness

Phase 3

Initiation

WAKIX® (pitolisant) Details
Muscle degeneration, Muscle weakness, Myotonic Dystrophy Type 1

Phase 2

Data readout

ZYN002 Details
no known indication

Phase 2

Data readout